NR
NRSN.US Neurosense Therapeutics Ltd
- Market cap
- USD 3.21M
- P/E
- -
- P/B
- 2.64x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is NRSN.US undervalued?
Graham numberThe Graham number of Neurosense Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neurosense Therapeutics Ltd fundamental analysis
No fundamental analysis for Neurosense Therapeutics Ltd yet.
Neurosense Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical tr…
Full company profileNeurosense Therapeutics Ltd financial statements
Neurosense Therapeutics Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -3.00K | -3.00K | -89.0K | -97.0K | -22.0K | - |
| Operating Income | -1.24M | -2.89M | -5.59M | -13.6M | -12.0M | -9.90M | -11.1M |
| EBITDA | 13.0K | -2.83M | -2.88M | -12.2M | -9.64M | -9.88M | -11.1M |
| Net Income | -1.23M | -2.83M | -4.04M | -12.3M | -10.1M | -10.2M | -11.1M |
| EPS | -4.50 | -10 | -7.44 | -21 | -15 | -11 | -8.73 |
| Balance Sheet | |||||||
| Total Assets | 955K | 779K | 11.4M | 7.71M | 3.19M | 4.58M | 1.03M |
| Total Liabilities | 37.0K | 120K | 2.43M | 2.09M | 4.94M | 1.99M | 2.59M |
| Shareholders' Equity | 918K | 659K | 9.01M | 5.62M | -1.76M | 2.58M | -1.56M |
| Cash & Short-term Investments | 895K | 699K | 11.1M | 7.09M | 2.64M | 3.38M | 166K |
| Total Debt | - | - | 1.83M | 211K | 142K | 73.0K | 170K |
| Cash Flow | |||||||
| Operating Cash Flow | -582K | -695K | -1.54M | -7.59M | -8.35M | -10.1M | -7.67M |
| Capital Expenditure | 7.00K | 9.00K | 17.0K | 70.0K | 29.0K | 3.00K | 8.00K |
| Free Cash Flow | -589K | -704K | -1.56M | -7.66M | -8.38M | -10.1M | -7.68M |
| Ratios | |||||||
| ROE | -133.7% | -429.1% | -44.9% | -219.6% | - | -395.3% | - |
| ROA | -128.5% | -363.0% | -35.4% | -160.1% | -317.3% | -223.2% | -1,082.2% |
| Debt to Equity | - | - | 0.20x | 0.04x | - | 0.03x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neurosense Therapeutics Ltd dividends
Neurosense Therapeutics Ltd has not paid dividends in the last 7 fiscal years.
Last stock split: 1:20 on Sep 14, 2026.
Who owns Neurosense Therapeutics Ltd
- Insiders 31.42%
- Institutions 0.17%
- Public & others 68.41%
- Shares outstanding 1.90M
- Free float 1.19M
Top funds holding NRSN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 15.9K | 0.04% | 0.00% | Aug 2026 |
Top institutions holding NRSN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| UBS Group AG | 109K | 0.29% | +121.27% | Jun 2026 |
| Independent Advisor Alliance | 100K | 0.26% | +100.00% | Jun 2026 |
| Yorkville Advisors Global, LP | 78.0K | 0.21% | 0.00% | Jun 2026 |
| Commonwealth Equity Services, LLC | 22.8K | 0.06% | 0.00% | Jun 2026 |
| PNC Financial Services Group Inc | 21.2K | 0.06% | 0.00% | Jun 2026 |
| Pathstone Holdings LLC | 16.5K | 0.04% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 15.9K | 0.04% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 11.5K | 0.03% | 0.00% | Jun 2026 |
| Creative Planning Inc | 11.4K | 0.03% | -4.21% | Jun 2026 |
| HRT FINANCIAL LLC | 10.5K | 0.03% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 1.00K | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 255.00 | 0.00% | -3.77% | Jun 2026 |
| Meitav Dash Investments Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Jane Street Group LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Two Sigma Investments LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Neurosense Therapeutics Ltd company profile
- Company name
- Neurosense Therapeutics Ltd
- Ticker
- NRSN.US
- ISIN
- IL0011809592
- Exchange
- USA Stocks
- Listed since
- Dec 9, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Fiscal year end
- December
- Address
- Building B, Herzliya, Israel, 4672562
- Phone
- 972 9 799 6183
- Website
- neurosense-tx.com
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Neurosense Therapeutics Ltd management
3- Mr. Alon Ben-NoonCo-Founder, CEO & Director · born 1979
- Mr. Or EisenbergChief Financial Officer · born 1981
- Dr. Niva Russek-Blum Ph.D.Chief Technology Officer · born 1979